- Home
- Publications
- Publication Search
- Publication Details
Title
Engineered antibody fusion proteins for targeted disease therapy
Authors
Keywords
-
Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 42, Issue 12, Pages 1064-1081
Publisher
Elsevier BV
Online
2021-10-25
DOI
10.1016/j.tips.2021.09.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
- (2021) Chan Gyu Lee et al. Frontiers in Pharmacology
- A novel antibody-interleukin-15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine and inhibits metastasis
- (2021) Riccardo Corbellari et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension
- (2021) Baptiste Gouyou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
- (2021) Eric J. Hsu et al. Nature Communications
- The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control
- (2021) Roberta Lucchi et al. ACS Central Science
- A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
- (2021) Yutong Xing et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand
- (2021) Qiyu Li et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies
- (2020) Leander Huyghe et al. EMBO Molecular Medicine
- Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
- (2020) Maciej Kujawski et al. OncoImmunology
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
- (2020) Hanne Lind et al. Journal for ImmunoTherapy of Cancer
- The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors
- (2020) Riccardo Corbellari et al. ANTI-CANCER DRUGS
- A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.
- (2020) Ravit Geva et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity
- (2020) Shanling Shen et al. Frontiers in Immunology
- Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
- (2020) Ronit Mazor et al. Frontiers in Immunology
- Anticancer Immunotoxins, Challenges, and Approaches
- (2020) Maryam Dashtiahangar et al. CURRENT PHARMACEUTICAL DESIGN
- Therapeutic Fc‐fusion proteins: Current analytical strategies
- (2020) Bastiaan L. Duivelshof et al. JOURNAL OF SEPARATION SCIENCE
- Immunocytokines are a promising immunotherapeutic approach against glioblastoma
- (2020) Tobias Weiss et al. Science Translational Medicine
- A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo
- (2020) Tiziano Ongaro et al. Oncotarget
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions
- (2020) M. Knödler et al. BIOTECHNOLOGY ADVANCES
- Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
- (2019) Neelakshi Mungra et al. Oncotarget
- Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease
- (2019) Priya Kishnani et al. MOLECULAR GENETICS AND METABOLISM
- Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
- (2019) Lawrence H. Cheung et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Considerations for the Design of Antibody-Based Therapeutics
- (2019) Dennis R. Goulet et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin
- (2019) Raquel Ibáñez-Pérez et al. OncoImmunology
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
- (2019) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors
- (2019) Emanuele Puca et al. INTERNATIONAL JOURNAL OF CANCER
- Application of therapeutic protein-based fusion toxins
- (2019) Hyun-Jong Ahn et al. Molecular & Cellular Toxicology
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
- (2019) Patrizia Murer et al. New Biotechnology
- Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases
- (2019) Zhengqiu Zhou et al. TRENDS IN MOLECULAR MEDICINE
- A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Daniel O. Persky et al. BLOOD
- Critical Issues in the Development of Immunotoxins for Anticancer Therapy
- (2019) Ji-Sun Kim et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
- (2019) Zhichen Sun et al. Nature Communications
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
- (2019) Christine Alewine et al. CLINICAL CANCER RESEARCH
- Etanercept for the treatment of rheumatoid arthritis
- (2018) Sizheng Zhao et al. Immunotherapy
- Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity
- (2018) Barbara Ziffels et al. Immunotherapy
- Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads
- (2018) Anja Sophie Schmid et al. JOURNAL OF BIOTECHNOLOGY
- Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model
- (2018) Hans D. Menssen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
- (2018) Roberto Giugliani et al. Orphanet Journal of Rare Diseases
- Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis
- (2018) Anja Sophie Schmid et al. RHEUMATOLOGY
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
- (2018) Shengjian Huang et al. Blood Cancer Journal
- Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
- (2018) Cornelia Hutmacher et al. ADVANCED DRUG DELIVERY REVIEWS
- Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
- (2018) Jamie B. Spangler et al. JOURNAL OF IMMUNOLOGY
- Modular Pore-Forming Immunotoxins with Caged Cytotoxicity Tailored by Directed Evolution
- (2018) Natalie L. Mutter et al. ACS Chemical Biology
- Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice
- (2018) Anje Cauwels et al. JOURNAL OF AUTOIMMUNITY
- Immunotoxins in cancer therapy: Review and update
- (2017) Bahman Akbari et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease
- (2017) Haiqing Yi et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy
- (2017) Roberto De Luca et al. MOLECULAR CANCER THERAPEUTICS
- Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody–Iduronidase Fusion Protein
- (2017) Ruben J. Boado et al. MOLECULAR PHARMACEUTICS
- Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
- (2017) Jonathan K. Fallon et al. Oncotarget
- Current progress in innovative engineered antibodies
- (2017) William R. Strohl Protein & Cell
- A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
- (2017) Anje Cauwels et al. OncoImmunology
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells
- (2016) Xinxin Lv et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN versus IFN in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
- (2016) R. E. Hawkins et al. CLINICAL CANCER RESEARCH
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
- (2016) Franziska Bootz et al. DRUG DISCOVERY TODAY
- Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination
- (2016) Surinder K. Sharma et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The future of antiviral immunotoxins
- (2016) Katja Spiess et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
- (2016) Frieder Bauss et al. Molecular Oncology
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity
- (2015) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
- (2015) A. E. Frankel et al. HAEMATOLOGICA
- Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
- (2015) A. E. Frankel et al. HAEMATOLOGICA
- The immunocytokine NHS-IL12 as a potential cancer therapeutic
- (2015) Jonathan Fallon et al. Oncotarget
- Antimalarial Activity of Granzyme B and Its Targeted Delivery by a Granzyme B–Single-Chain Fv Fusion Protein
- (2014) Stephanie Kapelski et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Insulin receptor antibody-iduronate 2-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys
- (2014) Ruben J. Boado et al. BIOTECHNOLOGY AND BIOENGINEERING
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
- (2014) Marie Vincent et al. mAbs
- The therapeutic monoclonal antibody market
- (2014) Dawn M Ecker et al. mAbs
- Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
- (2014) Tim Eisen et al. Current Oncology Reports
- Chimera of IL-2 Linked to Light Chain of anti-IL-2 mAb Mimics IL-2/anti-IL-2 mAb Complexes Both Structurally and Functionally
- (2013) Jakub Tomala et al. ACS Chemical Biology
- Blood-Brain Barrier Molecular Trojan Horse Enables Imaging of Brain Uptake of Radioiodinated Recombinant Protein in the Rhesus Monkey
- (2013) Ruben J. Boado et al. BIOCONJUGATE CHEMISTRY
- Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy
- (2013) V. Chandramohan et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia
- (2010) Ruolan Liu et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein
- (2010) Ruben J. Boado et al. JOURNAL OF BIOTECHNOLOGY
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
- (2010) Yenkel Grinberg-Bleyer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
- (2010) Göran Forsberg et al. JOURNAL OF IMMUNOTHERAPY
- Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse
- (2010) R. J. Boado et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
- (2009) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression
- (2009) Kylie E. Webster et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
- (2009) Daniel A. Vallera et al. LEUKEMIA RESEARCH
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
- (2008) Qizhi Tang et al. IMMUNITY
- Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation
- (2008) G.-H. Jin et al. INTERNATIONAL IMMUNOLOGY
- A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo
- (2008) Alessandra Villa et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy
- (2008) G. Verdeil et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GDNF fusion protein for targeted-drug delivery across the human blood–brain barrier
- (2007) Ruben J. Boado et al. BIOTECHNOLOGY AND BIOENGINEERING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started